Kyverna Therapeutics (KYTX) Asset Writedowns and Impairment (2025)
Kyverna Therapeutics' (KYTX) quarterly Asset Writedowns and Impairment came in at $648000.0 in Q1 2025.
Analysis
Kyverna Therapeutics (KYTX) Asset Writedowns and Impairment (2025) Analysis & Trends
Kyverna Therapeutics (KYTX) has 1 years of Asset Writedowns and Impairment data on file, last reported at $648000.0 in Q1 2025.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $648000.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $648000.0 (changed N/A YoY) and the FY2025 annual result came in at $648000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment steadied at $648000.0 in Q1 2025.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $648000.0 in Q1 2025 to a low of $648000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Kyverna Therapeutics | 505.44 Mn | 505.44 Mn | - |